Dr. Yun Yen M.D. Ph.D. serves as Independent Director of the Company. He is a founder of our genetic testing business and was appointed as a member of our Board in September 2016 in connection with our initial public offering. Dr. Yen serves as a Chair Professor at Taipei Medical University in Taiwan, as well as an Affiliate Professor at the California Institute of Technology. Dr. Yen’s prior experience includes service as the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics at the City of Hope Comprehensive Cancer Center from 2008 until 2014, and Chair of the City of Hope’s Molecular Pharmacology Department and Associate Director for Translational Research at the City of Hope Comprehensive Cancer Center from 2005 until 2014. Dr. Yen holds memberships in numerous professional organizations and has published more than 140 abstracts and peer-reviewed journal articles. Dr. Yen received a M.D. from Taipei Medical College in 1982 and a Ph.D. in Pathology and Cell Biology from Thomas Jefferson University in 1988.
As the Independent Director of Fulgent Genetics Inc, the total compensation of Yun Yen at Fulgent Genetics Inc is $53,500. There are 9 executives at Fulgent Genetics Inc getting paid more, with Paul Kim having the highest compensation of $823,481.
Yun Yen is 65, he's been the Independent Director of Fulgent Genetics Inc since 2016. There are 2 older and 7 younger executives at Fulgent Genetics Inc. The oldest executive at Fulgent Genetics Inc is John Bolger, 73, who is the Independent Director.
Yun's mailing address filed with the SEC is 4978 Santa Anita Ave Suite 205, Temple City, CA 91780, USA.
Over the last 9 years, insiders at Fulgent Genetics Inc have traded over $32,817,108 worth of Fulgent Genetics Inc stock and bought 1,136,382 units worth $9,558,758 . The most active insiders traders include Hanlin Gao, Ming Hsieh a Paul Kim. On average, Fulgent Genetics Inc executives and independent directors trade stock every 28 days with the average trade being worth of $848,250. The most recent stock trade was executed by Paul Kim on 3 September 2024, trading 1,674 units of FLGT stock currently worth $36,761.
mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques
Fulgent Genetics Inc executives and other stock owners filed with the SEC include: